46 -8 (58) 2023 — Kholikova A.O., Kenzhaeva D.I. — SIGNIFICANCE OF QUESTIONNAIRE ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH THYROID DISEASES

SIGNIFICANCE OF QUESTIONNAIRE ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH THYROID DISEASES

 Kholikova A.O., Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y. Kh. Turakulov, Specialized Hospital

Kenzhaeva D.I. Kashkadarya branch of the Republican specialized endocrinology scientific and practical medical center

Resume

 The purpose of the study was to review the literature on the assessment of QoL in patients with thyroid diseases by using various questionnaires (questionnaires).

Research methods. We searched the Pubmed, Cochrane Library, and Google Scholar databases to identify studies assessing the QoL of patients with thyroid disease. using thyroid-specific questionnaires.

 The resulting studies were divided into the following three groups: (1) questionnaires on benign thyroid disease, (2) questionnaires on malignant thyroid diseases, and (3) questionnaires on endocrine orbitopathy.

 Research results. Four of the selected 16 questionnaires (QoL questionnaires) were devoted to benign thyroid diseases, including hypothyroidism and Graves’ disease. Six questionnaires were assigned to malignant diseases of the thyroid gland, six questionnaires – to the third category “endocrine orbitopathy”.

 Conclusions: 1. For various benign thyroid diseases, the ThyPRO questionnaire and its abbreviated version ThyPRO-39 are the most appropriate questionnaires for clinical use. For hypothyroidism, Thy-D-QoL can be used as an alternative.

2. The choice of a quality of life questionnaire for malignant thyroid diseases should be decided individually.

3. To assess the quality of life in patients with endocrine orbitopathy, it is best to validate the GO-QOL.

4. As a short clinical screening questionnaire or for questions in which quality of life is a secondary outcome, TED-QoL appears to be a suitable alternative.

Keywords: questionnaires, quality of life, thyroid gland

First page

264

Last page

270

For citation: Kholikova A.O., Kenzhaeva D.I. – SIGNIFICANCE OF QUESTIONNAIRE ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH THYROID DISEASES //New Day in Medicine 2023 8(58): 264-270 https://newdaymedicine.com/index.php/2023/08/31/l-334/

LIST OF REFERENCES:

1. Faggiano A, Del Prete M, Marciello F, Marotta V, Ramundo V, Colao A. Thyroid diseases in elderly. //Minerva Endocrinol. 2011;36(3):211‐231.
2. Vanderpump MP. The epidemiology of thyroid disease. //Br Med Bull. 2011;99:39‐51.
3. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, Morris AD. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the thyroid epidemiology audit and research study (TEARS). //Clin Endocrinol. 2008;68(2):311‐316.
4. Scerrino G, Morfino G, Paladino NC, et al. Does thyroid surgery for Graves’ disease improve health‐related quality of life? //Surg Today. 2013;43(12):1398‐1405.
5. Watt T, Groenvold M, Rasmussen AK, et al. Quality of life in patients with benign thyroid disorders. A Review. // Eur J Endocrinol. 2006;154(4):501‐510.
6. Wojewoda B, Juzwiszyn J, Rosińczuk‐Tonderys J. Quality of life after surgical treatment of thyroid gland diseases. //Rocz Akad Med Bialymst. 2005;50(Suppl 1):133‐136.
7. Guyatt GH, Feeny DH, Patrick DL. Measuring health‐related quality of life. // Ann Intern Med. 1993;118(8):622‐629.
8. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. //J Clin Epidemiol. 2007;60(1):34‐42
9. Terwee CB, Mokkink LB, Knol DL, Ostelo RWJG, Bouter LM, de Vet HCW. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. //Qual Life Res. 2012;21(4):651‐657.
10. Mokkink LB, De Vet HC, Prinsen CA, et al. COSMIN risk of bias checklist for systematic reviews of patient‐reported outcome measures. // Qual Life Res. 2018;27(5):1171‐1179.]
11. Prinsen CA, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient‐reported outcome measures. //Qual Life Res. 2018;27(5):1147‐1157.
12. Terwee CB, Prinsen CA, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient‐reported outcome measures: a Delphi study. //Qual Life Res. 2018;27(5):1159‐1170.
13. Wong CK, Lang BH, Lam CL. A systematic review of quality of thyroid‐specific health‐related quality‐of‐life instruments recommends ThyPRO for patients with benign thyroid diseases. // J Clin Epidemiol. 2016;78:63‐72
14. Watt T, Hegedüs L, Groenvold M, et al. Validity and reliability of the novel thyroid‐specific quality of life questionnaire, ThyPRO. //Eur J Endocrinol. 2010;162(1):161‐167. 
15. Watt T, Bjorner JB, Groenvold M, et al. Development of a short version of the thyroid‐related patient‐reported outcome ThyPRO. //Thyroid. 2015;25(10):1069‐1079
16. Kaniuka‐Jakubowska S, Lewczuk A, Majkowicz M, et al. Nontoxic goiter (NTG) and radioiodine: what do patients think about it? Quality of life in patients with NTG before and after 131‐I therapy. //Front Endocrinol (Lausanne). 2018;9:114
17. McMillan CV, Bradley C, Woodcock A, Razvi S, Weaver JU. Design of new questionnaires to measure quality of life and treatment satisfaction in hypothyroidism. //Thyroid. 2004;14(11):916‐925.
18. McMillan C, Bradley C, Razvi S, Weaver J. Evaluation of new measures of the impact of hypothyroidism on quality of life and symptoms: the ThyDQoL and ThySRQ. //Value Health. 2008;11(2):285‐294.
19. Fahrenfort JJ, Wilterdink AM, van der Veen EA. Long‐term residual complaints and psychosocial sequelae after remission of hyperthyroidism. // Psychoneuroendocrinology. 2000;25(2):201‐211.
20. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L‐thyroxine therapy in subclinical hypothyroidism. A double‐blind, placebo‐controlled trial. //Ann Intern Med. 1984;101(1):18‐24.